| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Acute renal allograft rejection after immune checkpoint inhibitor therapy for metastatic melanoma
|
Spain, L.
|
|
|
27 |
6 |
p. 1135-1137
|
artikel
|
| 2 |
A genomic case study of mixed fibrolamellar hepatocellular carcinoma
|
Griffith, O.L.
|
|
|
27 |
6 |
p. 1148-1154
|
artikel
|
| 3 |
Anti-tumour activity of platinum compounds in advanced prostate cancer—a systematic literature review
|
Hager, S.
|
|
|
27 |
6 |
p. 975-984
|
artikel
|
| 4 |
A phase I dose-escalation study of apatorsen (OGX-427), an antisense inhibitor targeting heat shock protein 27 (Hsp27), in patients with castration-resistant prostate cancer and other advanced cancers
|
Chi, K.N.
|
|
|
27 |
6 |
p. 1116-1122
|
artikel
|
| 5 |
A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancer
|
O'Neil, B.H.
|
|
|
27 |
6 |
p. 1180
|
artikel
|
| 6 |
A phase III trial of exemestane plus bevacizumab maintenance therapy in patients with metastatic breast cancer after first-line taxane and bevacizumab: a GINECO group study
|
Trédan, O.
|
|
|
27 |
6 |
p. 1020-1029
|
artikel
|
| 7 |
Are strong opioids equally effective and safe in the treatment of chronic cancer pain? A multicenter randomized phase IV ‘real life’ trial on the variability of response to opioids
|
Corli, O.
|
|
|
27 |
6 |
p. 1107-1115
|
artikel
|
| 8 |
Breast cancer genetic risk profile is differentially associated with interval and screen-detected breast cancers
|
Li, J.
|
|
|
27 |
6 |
p. 1181
|
artikel
|
| 9 |
Breast cancer incidence and mortality: trends over 40 years among women in Shanghai, China
|
Huang, Z.
|
|
|
27 |
6 |
p. 1129-1134
|
artikel
|
| 10 |
Cancer-associated toll-like receptor modulation and insinuation in infection susceptibility: association or coincidence?
|
Khan, A.A.
|
|
|
27 |
6 |
p. 984-997
|
artikel
|
| 11 |
Cetuximab continuation after first progression in metastatic colorectal cancer (CAPRI-GOIM): a randomized phase II trial of FOLFOX plus cetuximab versus FOLFOX
|
Ciardiello, F.
|
|
|
27 |
6 |
p. 1055-1061
|
artikel
|
| 12 |
Combination of the MEK inhibitor pimasertib with BTK or PI3K-delta inhibitors is active in preclinical models of aggressive lymphomas
|
Gaudio, E.
|
|
|
27 |
6 |
p. 1123-1128
|
artikel
|
| 13 |
Comparison of prognostic and predictive impact of genomic or central grade and immunohistochemical subtypes or IHC4 in HR+/HER2- early breast cancer: WSG-AGO EC-Doc Trial
|
Gluz, O.
|
|
|
27 |
6 |
p. 1035-1040
|
artikel
|
| 14 |
Diagnostic Gleason score and castration-resistant prostate cancer
|
Jayaram, A.
|
|
|
27 |
6 |
p. 962-964
|
artikel
|
| 15 |
Editorial board
|
|
|
|
27 |
6 |
p. ii-iii
|
artikel
|
| 16 |
Health-related quality of life in women with recurrent ovarian cancer receiving paclitaxel plus trebananib or placebo (TRINOVA-1) †
|
Fujiwara, K.
|
|
|
27 |
6 |
p. 1006-1013
|
artikel
|
| 17 |
Incidence and prognostic impact of other cancers in a population of long-term survivors of chronic lymphocytic leukemia
|
Falchi, L.
|
|
|
27 |
6 |
p. 1100-1106
|
artikel
|
| 18 |
Large-scale prospective pharmacogenomics study of oxaliplatin-induced neuropathy in colon cancer patients enrolled in the JFMC41-1001-C2 (JOIN Trial)
|
Kanai, M.
|
|
|
27 |
6 |
p. 1143-1148
|
artikel
|
| 19 |
Lessons from clinical trials on quality-of-life assessment in ovarian cancer trials
|
Di Maio, M.
|
|
|
27 |
6 |
p. 961-962
|
artikel
|
| 20 |
Long-term outcomes after adjuvant treatment of sequential versus combination docetaxel with doxorubicin and cyclophosphamide in node-positive breast cancer: BCIRG-005 randomized trial
|
Mackey, J.R.
|
|
|
27 |
6 |
p. 1041-1047
|
artikel
|
| 21 |
Minimal residual disease-based effect and long-term outcome of first-line dasatinib combined with chemotherapy for adult Philadelphia chromosome-positive acute lymphoblastic leukemia
|
Yoon, J.-H.
|
|
|
27 |
6 |
p. 1081-1088
|
artikel
|
| 22 |
Ocular toxicities of MEK inhibitors and other targeted therapies
|
Stjepanovic, N.
|
|
|
27 |
6 |
p. 998-1005
|
artikel
|
| 23 |
Olaparib monotherapy in patients with advanced relapsed ovarian cancer and a germline BRCA1/2 mutation: a multistudy analysis of response rates and safety
|
Matulonis, U.A.
|
|
|
27 |
6 |
p. 1013-1019
|
artikel
|
| 24 |
On the tumor risk from dental diagnostic X-ray exposure
|
Jargin, S.V.
|
|
|
27 |
6 |
p. 1177
|
artikel
|
| 25 |
Osimertinib (AZD9291)—a science-driven, collaborative approach to rapid drug design and development
|
Yver, A.
|
|
|
27 |
6 |
p. 1165-1170
|
artikel
|
| 26 |
Progression-free survival as surrogate end point for overall survival in clinical trials of HER2-targeted agents in HER2-positive metastatic breast cancer †
|
Michiels, S.
|
|
|
27 |
6 |
p. 1029-1034
|
artikel
|
| 27 |
Pulmonary sarcoidosis induced by the anti-PD1 monoclonal antibody pembrolizumab
|
Cousin, S.
|
|
|
27 |
6 |
p. 1178-1179
|
artikel
|
| 28 |
Quality of life with palbociclib plus fulvestrant in previously treated hormone receptor-positive, HER2-negative metastatic breast cancer: patient-reported outcomes from the PALOMA-3 trial
|
Harbeck, N.
|
|
|
27 |
6 |
p. 1047-1054
|
artikel
|
| 29 |
Reduced intensity allogeneic stem cell transplantation for follicular lymphoma relapsing after an autologous transplant achieves durable long-term disease control: an analysis from the Lymphoma Working Party of the EBMT †
|
Robinson, S.P.
|
|
|
27 |
6 |
p. 1088-1094
|
artikel
|
| 30 |
Reply to the letter to the editor ‘A randomized trial of intensive versus minimal surveillance of patients with resected Dukes B2-C colorectal carcinoma’ by Hines et al.
|
Rosati, G.
|
|
|
27 |
6 |
p. 1171
|
artikel
|
| 31 |
Reply to the letter to the editor ‘On the tumor risk from dental diagnostic X-ray exposure’ by Jargin
|
Lin, M.-C.
|
|
|
27 |
6 |
p. 1177-1178
|
artikel
|
| 32 |
Reply to the letter to the editor ‘Survival in young adults diagnosed with follicular lymphoma’ by Calvo et al.
|
Conconi, A.
|
|
|
27 |
6 |
p. 1173
|
artikel
|
| 33 |
Reply to the letter to the editor ‘What is the clinical impact of the LUX-Lung 5 trial?’ by Addeo
|
Schuler, M.
|
|
|
27 |
6 |
p. 1172-1173
|
artikel
|
| 34 |
Risk factors, prevalence, and course of severe fatigue after breast cancer treatment: a meta-analysis involving 12 327 breast cancer survivors
|
Abrahams, H.J.G.
|
|
|
27 |
6 |
p. 965-974
|
artikel
|
| 35 |
Rociletinib: has the TIGER lost a few of its stripes?
|
Dhingra, K.
|
|
|
27 |
6 |
p. 1161-1164
|
artikel
|
| 36 |
Single-agent capecitabine as maintenance therapy after induction of XELOX (or FOLFOX) in first-line treatment of metastatic colorectal cancer: randomized clinical trial of efficacy and safety
|
Luo, H.Y.
|
|
|
27 |
6 |
p. 1074-1081
|
artikel
|
| 37 |
Table of Contents
|
|
|
|
27 |
6 |
p. iv-vi
|
artikel
|
| 38 |
Targeted treatment and immunotherapy in leptomeningeal metastases from melanoma
|
Geukes Foppen, M.H.
|
|
|
27 |
6 |
p. 1138-1142
|
artikel
|
| 39 |
The use of ipilimumab in patients with rheumatoid arthritis and metastatic melanoma
|
Lee, B.
|
|
|
27 |
6 |
p. 1174-1177
|
artikel
|
| 40 |
The value of routine bone marrow biopsy in patients with diffuse large B-cell lymphoma staged with PET/CT: a Danish-Canadian study †
|
Alzahrani, M.
|
|
|
27 |
6 |
p. 1095-1099
|
artikel
|
| 41 |
Tumor MGMT promoter hypermethylation changes over time limit temozolomide efficacy in a phase II trial for metastatic colorectal cancer
|
Amatu, A.
|
|
|
27 |
6 |
p. 1062-1067
|
artikel
|
| 42 |
Tumourigenic non-small-cell lung cancer mesenchymal circulating tumour cells: a clinical case study
|
Morrow, C.J.
|
|
|
27 |
6 |
p. 1155-1160
|
artikel
|
| 43 |
Utility of a molecular prescreening program in advanced colorectal cancer for enrollment on biomarker-selected clinical trials †
|
Overman, M.J.
|
|
|
27 |
6 |
p. 1068-1074
|
artikel
|
| 44 |
What is the clinical impact of the LUX-Lung 5 trial?
|
Addeo, A.
|
|
|
27 |
6 |
p. 1171-1172
|
artikel
|
Tijdschrift beschrijving